1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BioView Ltd.

BioView Ltd.

TTASE:BIOV
5,001.00
ILA
-325.00
(-6.10%)
4.88BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
171.57
223.93
251.88
239.62
198.91
178.95
252.17
184.63
218.32
215.24
256.76
193.18
14.69
- -
Basic EPS, GAAP
-8.02
15.61
29.66
31.94
-8.97
-13.12
17.79
6.29
15.63
4.34
2.83
-23.7
-11.3
- -
Free Cash Flow per Basic Share
-23.24
23.44
32.47
25.97
-1.06
-10.65
16.12
3.54
18.52
3.77
-0.89
-23.65
-2.29
- -
Dividend per Share
- -
- -
- -
- -
19.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
116.5
134.28
166.1
198.15
167.96
160.24
175.46
179.37
194.33
203.31
203.06
177.21
67.74
212.24
Tangible Book Value per Share
111.61
130.45
162.6
194.68
165.11
159.45
175.46
179.37
194.33
203.31
203.06
177.21
67.74
212.24
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Sales/Revenue/Turnover
23
30
35
33
28
25
36
26
31
29
35
26
20
- -
Operating Margin (%)
-3.22
4.88
10.8
13.98
-1.02
-10.41
12.18
8.36
11.64
0.35
1.81
-11.58
-39.15
- -
Depreciation Expense
1
- -
- -
- -
- -
1
1
1
1
1
2
2
2
- -
Net Income, GAAP
-1
2
4
4
-1
-2
3
1
2
1
- -
-3
-15
- -
Effective Tax Rate (%)
- -
5.89
- -
4.79
- -
- -
25.03
22.52
18.6
32.91
51.94
- -
- -
- -
Profit Margin (%)
-4.67
6.97
11.77
13.33
-4.51
-7.33
7.06
3.41
7.16
2.01
1.1
-12.27
-76.93
- -
Working Capital
12
14
18
22
17
16
18
18
20
21
20
15
8
21
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
4
3
2
- -
1
2
Total Equity
16
18
23
28
23
23
25
25
27
28
27
23
9
29
Return on Invested Capital (%)
- -
13.97
- -
17.83
- -
- -
10.13
3.45
8.24
2.4
1.16
- -
- -
- -
Return on Capital (%)
- -
12.46
- -
17.54
- -
- -
10.25
3.41
8.14
2.33
1.69
- -
- -
- -
Return on Common Equity (%)
-6.65
12.46
19.75
17.54
-4.9
-8.03
10.59
3.53
8.36
2.12
1.38
-12.53
-94.76
- -

Capital Structure

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
ST Debt
1
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
54
51
49

Working Capital

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
Total Current Assets
30
31
31
Cash, Cash Equivalents & STI
19
19
18
Accounts Receivable, Net
6
5
7
Inventories
5
5
5
Total Current Liabilities
8
10
10
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.37%
-13.18%
-58.97%
Free Cash Flow
317.42%
542.12%
-0.99%
Net Income, GAAP
-86.79%
-99.14%
387.04%
Sales/Revenue/Turnover
-3.12%
-3.24%
-22.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
35
2024
- -
- -
26
2025
- -
- -
20

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.83
2024
- -
- -
-23.7
2025
- -
- -
-11.3

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Daniel Klain
Full Time Employees
31
Sector
Health technology
Industry
Medical specialties
Address
3 Pekeris Street Rehovot HM Israel 7670203
IPO Date
Mar 7, 2006
Website
bioview.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bio-View Ltd (BIOV.TA) develops, manufactures and markets automated cell imaging and analysis solutions for cytology, cytogenetic and pathology applications in clinical and research laboratories worldwide. Founded in 1998 and headquartered in Rehovot, Israel, the company offers a comprehensive suite of products including Accord, a semi-automated fluorescent imaging workbench; Accord Plus, an automatic system for scanning, analyzing and sorting FISH and karyotype samples; Allegro Plus, a fluorescent imaging system detecting chromosomal aberrations such as amplifications, translocations, inversions and deletions; DUET-3, a multi-application automated imaging system; Encore, an automated barcode reader for batch scanning; DeNovo, a scanning system for circulating tumor cell detection, analysis and characterization from peripheral blood; Solo Workstation and Solo Touch Workstation for offline review and analysis; and SoloWeb, a web-based platform for analysis, reporting and consulting. Bio-View operates primarily in the medical devices sector, targeting cancer diagnostics and genetic testing markets with installations across Israel and international regions. In recent developments, the company maintains a strategic partnership with ANGLE plc to co-develop a liquid biopsy assay for HER2 detection in circulating tumor cells for breast cancer, with promising initial results presented at the AACR International Liquid Biopsy Conference in December 2024.